share_log

Vivos Therapeutics | 424B5: Prospectus

Vivos Therapeutics | 424B5: Prospectus

Vivos Therapeutics | 424B5：募資說明書
美股SEC公告 ·  09/20 07:02

Moomoo AI 已提取核心訊息

Vivos Therapeutics, a medical technology company, has announced the direct offering of 1,363,812 shares of its common stock to several institutional investors. The offering is pursuant to a prospectus supplement and the accompanying prospectus dated February 14, 2022. The shares are being offered at a price of $3.15 per share, with the common stock listed on The NASDAQ Capital Market under the symbol 'VVOS.' The last reported sale price of Vivos' common stock was $4.13 per share as of September 18, 2024. The offering is expected to close on or about September 20, 2024, subject to customary closing conditions. H.C. Wainwright & Co., LLC has been engaged as the exclusive placement agent for the offering. The net proceeds from the offering, estimated at approximately $3.8 million after deducting placement agent fees and offering expenses, are intended for working capital and general corporate purposes.
Vivos Therapeutics, a medical technology company, has announced the direct offering of 1,363,812 shares of its common stock to several institutional investors. The offering is pursuant to a prospectus supplement and the accompanying prospectus dated February 14, 2022. The shares are being offered at a price of $3.15 per share, with the common stock listed on The NASDAQ Capital Market under the symbol 'VVOS.' The last reported sale price of Vivos' common stock was $4.13 per share as of September 18, 2024. The offering is expected to close on or about September 20, 2024, subject to customary closing conditions. H.C. Wainwright & Co., LLC has been engaged as the exclusive placement agent for the offering. The net proceeds from the offering, estimated at approximately $3.8 million after deducting placement agent fees and offering expenses, are intended for working capital and general corporate purposes.
vivos therapeutics，一家醫療技術公司，宣佈向幾家機構投資者直接發行1,363,812股普通股。此次發行是根據2022年2月14日的招股說明書和隨附招股說明書而進行的。這些股票的發行價格爲每股3.15美元，在納斯達克資本市場以「VVOS」爲標的進行交易。根據2024年9月18日的報告，vivos的普通股上市價格爲每股4.13美元。此次發行預計於2024年9月20日前後結束，需符合正常的交割條件。H.C. Wainwright & Co., LLC已經成爲此次發行的獨家配售代理。此次發行的淨收入預計約爲380萬美元，扣除配售代理費用和發行費用，用於營運資金和一般企業用途。
vivos therapeutics，一家醫療技術公司，宣佈向幾家機構投資者直接發行1,363,812股普通股。此次發行是根據2022年2月14日的招股說明書和隨附招股說明書而進行的。這些股票的發行價格爲每股3.15美元，在納斯達克資本市場以「VVOS」爲標的進行交易。根據2024年9月18日的報告，vivos的普通股上市價格爲每股4.13美元。此次發行預計於2024年9月20日前後結束，需符合正常的交割條件。H.C. Wainwright & Co., LLC已經成爲此次發行的獨家配售代理。此次發行的淨收入預計約爲380萬美元，扣除配售代理費用和發行費用，用於營運資金和一般企業用途。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間